{"schema_version":"secwatch.filing_event.v1","accession":"0001759138-26-000025","form_type":"8-K","ticker":"CABA","cik":"0001759138","company_name":"Cabaletta Bio, Inc.","filed_at":"2026-05-14T11:06:42+00:00","discovered_at":"2026-05-14T11:10:00.299239+00:00","generated_at":"2026-05-14T11:11:47.071365+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"confidence":"high","headline":"Cabaletta Bio Q1: R&D $37.4M, cash $116.6M; $150M equity raise; rese-cel advances","bullets":["R&D expenses $37.4M (up 29% YoY); G&A $6.9M (down 15% YoY); cash $116.6M as of March 31, 2026.","Post-quarter $150M registered direct offering closed in May 2026, extends cash runway into mid-2027.","Preconditioning-free rese-cel data presented at ASGCT; lowest dose showed drug-free responses in 4 PV patients.","Registrational RESET-Myositis trial progressing with BLA submission planned for 2027; higher dose and longer-term data expected 2H26.","Entered 10-year commercial supply agreement with Cellares for automated manufacturing of rese-cel."],"urls":{"canonical":"https://secwatch.observer/filing/0001759138-26-000025","json":"https://secwatch.observer/filing/0001759138-26-000025.json","markdown":"https://secwatch.observer/filing/0001759138-26-000025.md","text":"https://secwatch.observer/filing/0001759138-26-000025.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1759138/000175913826000025/0001759138-26-000025-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1759138/000175913826000025/caba-20260514.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-14T11:11:47.071365+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"13ebb8541baf77b3f5db2188aa2f73ea01cef949","claim":"Cabaletta Bio, Inc. reported financial results for the first quarter ended March 31, 2026.","evidence_excerpt":"On May 14, 2026, Cabaletta Bio, Inc. (the “Company”) announced its financial results for the first quarter ended March 31, 2026.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1759138/000175913826000025/0001759138-26-000025-index.htm","confidence":0.95,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the first quarter ended March 31, 2026"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}